Superworth

Kestra Medical Technologies free cash flow KMTS

Cash from operations less capital spending, by quarter and over the last twelve months, from 2024.

Last 12 months, to Jul 31, 2026
−$122.8M
Latest quarter, Q1 FY27
−$40.6M
Fiscal year 2026
−$116.6M

Kestra Medical Technologies' free cash flow was −$122.8M over the twelve months to Jul 31, 2026.

In its latest quarter, Q1 FY27, it was −$40.6M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2026−$116.6Mn/a
FY2025−$100.5Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q1 FY27−$40.6Mn/a−$122.8M
Q4 FY26−$28.4Mn/a−$116.6M
Q3 FY26−$28.2Mn/a−$119.7M
Q2 FY26−$25.6Mn/a−$113.6M
Q1 FY26−$34.4Mn/a−$110.4M
Q4 FY25−$31.4Mn/a−$100.5M
Q3 FY25−$22.1Mn/an/a
Q2 FY25−$22.5Mn/an/a
Q1 FY25−$24.5Mn/an/a

Against its peers

Companies in Medical - Instruments & Supplies nearest Kestra Medical Technologies' size, closest first, today.

CompanyFree cash flow yield
KMTSKestra Medical Technologies−7.2%
LMATLemaitre Vascular3.8%
EYENational Vision3.3%
INSPInspire Medical Systems5.7%
CDRECadre6.1%
UFPTUFP Technologiesn/m
BVSBioventus7.5%
STAAStaar Surgical−0.6%
IRMDIradimed2.3%
ATRCAtriCure1.8%
WRBYWarby Parker0.7%
Peer median3.3%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Kestra Medical Technologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.